Atherosclerosis: Immunopathogenesis and immunotherapy

Medical Science Monitor

Volumn 10, Issue 11, 2004, Pages

  Ohashi, Ryuji ^a   Mu, Hong ^a   Yao, Qizhi ^a   Chen, Changyi ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Cellular immunity; Humoral immunity; Immunopathogenesis; Immunotherapy

Indexed keywords

AUTOANTIGEN; CD36 ANTIGEN; CYTOKINE; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 65; INTERLEUKIN 10; SCAVENGER RECEPTOR;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELLULAR IMMUNITY; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE COURSE; HEREDITY; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; LIFESTYLE; MACROPHAGE; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

ANIMALS; ANTIBODY FORMATION; ARTERIOSCLEROSIS; AUTOIMMUNITY; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; INFECTION; VACCINATION;

EID: 9144247090     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Gerrity RG: The role of the monocyte in atherogenesis: II. Migration of foam cells from atherosclerotic lesions. Am J Pathol, 1981; 103: 191-200
2. Faggiotto A, Ross R, Harker L: Studies of hypercholesterolemia in the nonhuman primate. I. Changes that lead to fatty streak formation. Arteriosclerosis, 1984; 4: 323-40
3. Faggiotto A, Ross R: Studies of hypercholesterolemia in the nonhuman primate. II. Fatty streak conversion to fibrous plaque. Arteriosclerosis, 1984; 4: 341-56
4. Gu L, Okada Y, Clinton SK et al: Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell, 1998; 2: 275-81
5. Aiello RJ, Bourassa PA, Lindsey S et al: Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice, Arterioscler Thromb Vasc Biol, 1999; 19: 1518-25
6. Charo IF, Peters W: Chemokine receptor 2 (CCR2) in atherosclerosis, infectious diseases, and regulation of T-cell polarization. Microcirculation, 2003; 10: 259-64
7. Smith JD, Trogan E, Ginsberg M et al: Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA, 1995; 92: 8264-68
8. Schober A, Bernhagen J, Thiele M et al: Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation, 2004; 109: 380-85
9. Lucas AD, Greaves DR: Atherosclerosis: role of chemokines and macrophages. Expert Rev Mol Med, 2001; 2001: 1-18
10. Babaev VR, Gleaves LA, Carter KJ et al: Reduced atherosclerotic lesions in mice deficient for total or macrophage-specific expression of scavenger receptor-A. Arterioscler Thromb Vasc Biol, 2000; 20: 2593-99
11. Febbraio M, Podrez EA, Smith JD et al: Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest, 2000; 105: 1049-56
12. Zhang W, Yancey PG, Su YR et al: Inactivation of macrophage scavenger receptor class B type I promotes atherosclerotic lesion development in apolipoprotein E-deficient mice. Circulation, 2003; 108: 2258-63
13. Emeson EE, Shen ML, Bell CG et al: Inhibition of atherosclerosis in CD4 T-Cell-ablated and nude (nu/nu) C57BL/6 hyperlipidemic mice. Am J Pathol, 1996; 149: 675-85
14. Hansson GK: Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol, 2001; 21: 1876-90
15. Zhou X, Nicoletti A, Elhage R et al: Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation, 2000; 102: 2919-22
16. Mosmann TR, Sad S: The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today, 1996; 17: 138-46
17. Laurat E, Poirier B, Tupin E et al: In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation, 2001; 104: 197-202
18. Groux H: An overview of regulatory T cells. Microbes Infect, 2001; 3: 883-89
19. Roncarolo MG, Bacchetta R, Bordignon C et al: Type 1 T regulatory cells. Immunol Rev, 2001; 182: 68-79
20. Mcguirk P, Mills KH: Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases. Trends Immunol 2002; 23: 450-55
21. Groux H, O'garra A, Bigler M et al: A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature, 1997; 389: 737-42
22. Doetze A, Satoguina J, Burchard G et al: Antigen-specific cellular hyporesponsiveness in a chronic human helminth infection is mediated by T(h)3/T(r)1-type cytokines IL-10 and transforming growth factor-beta but not by a T(h)1 to T(h)2 shift. Int Immunol, 2000; 12: 623-30
23. Cavani A, Nasorri F, Prezzi C et al: Human CD4+ T lymphocytes with remarkable regulatory functions on dendritic cells and nickel-specific Th1 immune responses. J Invest Dermatol, 2000; 114: 295-302
24. Levings MK, Sangregorio R, Galbiati F et al: IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol, 2001; 166: 5530-39
25. Macdonald AJ, Duffy M, Brady MT et al: CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons. J Infect Dis, 2002; 185: 720-27
26. Mcguirk P, Mccann C, Mills KH: Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Med, 2002; 195: 221-31
27. Mallat Z, Gojova A, Brun V et al: Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation, 2003; 108: 1232-37
28. Ludewig B, Freigang S, Jaggi M et al: Linking immune-mediated arterial inflammation and cholesterol-induced atherosclerosis in a transgenic mouse model. Proc Natl Acad Sci USA, 2000; 97; 12752-57
29. Geng YJ, Henderson Le, Levesque EB et al: Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 1997; 17: 2200-8
30. Seitz CS, Kleindienst R, Xu Q et al: Coexpression of heat-shock protein 60 and intercellular-adhesion molecule-1 is related to increased adhesion of monocytes and T cells to aortic endothelium of rats in response to endotoxin. Lab Invest, 1996; 74; 241-52
31. Kleindienst R, Xu Q, Willeit J et al: Immunology of atherosclerosis. Demonstration of heat shock protein 60 expression and T lymphocytes bearing alpha/beta or gamma/delta receptor in human atherosclerotic lesions. Am J Pathol, 1993; 142: 1927-37
32. Melian A, Geng YJ, Sukhova GK et al: CD1 expression in human atherosclerosis. A potential mechanism for T cell activation by foam cells. Am J Pathol, 1999; 155; 775-86
33. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice I: Morphology, quantitation, tissue distribution. J Exp Med, 1973; 137: 1142-62
34. Bobryshev YV, Lord RS: Ultrastructural recognition of cells with dendritic cell morphology in human aortic intima. Contacting interactions of Vascular Dendritic Cells in athero-resistant and athero-prone areas of the normal aorta. Arch Histol Cytol, 1995; 58: 307-22
35. Bobryshev YV, Lord RS: Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reactions. Cardiovasc Res, 1998; 37: 799-810
36. Bobryshev YV, Lord RS, Rainer S et al: Vascula dendritic cells and atherosclerosis. Pathol Res Pract, 1996; 192: 462-67
37. Bobryshev YV: Dendritic cells and their involvement in atherosclerosis. Curr Opin Lipidol, 2000; 11: 511-17
38. Haberland ME, Fong D, Cheng L: Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science, 1988; 241: 215-18
39. Palinski W, Rosenfeld ME, Yla-Herttuala S et al: Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA, 1989; 86: 1372-76
40. Boyd HC, Gown AM, Wolfbauer G et al: Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. Am J Pathol, 1989; 135: 815-25
41. Bergmark C, Wu R, De Faire U et al: Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol, 1995; 15: 441-45
42. Maggi E, Chiesa R, Melissano G et al: LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. Arterioscler Thromb, 1994; 14: 1892-99
43. Lehtimaki T, Lehtinen S, Solakivi T et al: Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol, 1999; 19: 23-27
44. Bui MN, Sack MN, Moutsatsos G et al: Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis. Am Heart J, 1996; 131: 663-67
45. Salonen JT, Yla-Herttuala S, Yamamoto R et al: Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet, 1992; 339: 883-87
46. Wu R, Nityanand S, Berglund L et al: Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol, 1997; 17: 3159-63
47. Palinski W, Miller E, Witztum JL: Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA, 1995; 92: 821-25
48. Ameli S, Hultgardh-Nilsson A, Regnstrom J et al: Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol, 1996; 16: 1074-79
49. Zhou X, Caligiuri G, Hamsten A et al: LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol, 2001; 21: 108-14
50. Stemme S, Faber B. Holm J et al: T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA, 1995; 92: 3893-97
51. Caligiuri G, Nicoletti A, Zhou X et al: Effects of sex and age on atherosclerosis and autoimmunity in apoE-deficient mice. Atherosclerosis, 1999; 145: 301-8
52. Nicoletti A, Paulsson G, Caligiuri G et al: Induction of neonatal tolerance to oxidized lipoprotein reduces atherosclerosis in ApoE knock-out mice. Mol Med, 2000; 6: 283-90
53. Frostegard J, Wu R, Giscombe R et al: Induction of T-cell activation by oxidized low density lipoprotein. Arterioscler Thromb, 1992; 12: 461-67
54. Wick G, Schett G, Amberger A et al: Is atherosclerosis an immunologically mediated disease? Immunol Today, 1995; 16: 27-33
55. Frostegard J, Lemne C, Andersson B et al: Association of serum antibodies to heat-shock protein 65 with borderline hypertension. Hypertension, 1997; 29: 40-44
56. Pockley AG, Wu R, Lemne C et al: Circulating heat shock protein 60 is associated with early cardiovascular disease. Hypertension, 2000; 36: 303-7
57. Xu Q, Dietrich H, Steiner HJ et al: Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb, 1992; 12: 789-99
58. Maron R, Sukhova G, Faria AM et al: Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation, 2002; 106: 1708-15
59. Chmiela M, Kowalewicz-Kulbat M, Miszczak A et al: A link between Helicobacter pylori and/or Chlamydia spp. infections and atherosclerosis. FEMS Immunol Med Microbiol, 2003; 36: 187-92
60. Blasi F, Denti F, Erba M et al: Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms. J Clin Microbiol, 1996; 34: 2766-69
61. Juvonen J, Juvonen T, Laurila A et al: Immunohistochemical detection of Chlamydia pneumoniae in abdominal aortic aneurysms. Ann NY Acad Sci, 1996; 800: 236-38
62. Fong IW, Chiu B, Viira E et al: Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol, 1997; 35: 48-52
63. Benagiano M, Azzurri A, Ciervo A et al: T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci USA, 2003; 100: 6658-63
64. Dummer S, Lee A, Breinig MK et al: Investigation of cytomegalovirus infection as a risk factor for coronary atherosclerosis in the explanted hearts of patients undergoing heart transplantation. J Med Virol, 1994; 44: 305-9
65. Jacob HS: Newly recognized causes of atherosclerosis: the role of microorganisms and of vascular iron overload. J Lab Clin Med, 1994; 123: 808-16
66. Adler SP, Hur JK, Wang JB et al: Prior infection with cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis. J Infect Dis, 1998; 177: 209-12
67. Raza-Ahmad A, Klassen GA, Murphy DA et al: Evidence of type 2 herpes simplex infection in human coronary arteries at the time of coronary artery bypass surgery. Can J Cardiol, 1995; 11: 1025-29
68. Naghavi M, Barlas Z, Siadaty S et al: Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation, 2000; 102: 3039-45
69. Naghavi M, Wyde P, Litovsky S et al: Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein E-deficient mice. Circulation, 2003; 107: 762-68
70. Karmann K, Hughes CC, Schechner J et al: CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA, 1995; 92: 4342-46
71. Mach F, Schonbeck U, Sukhova GK et al: Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA, 1997; 94: 1931-36
72. Aukrust P, Muller F, Ueland T et al: Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation, 1999; 100: 614-20
73. Cipollone F, Mezzetti A, Porreca E et al: Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation, 2002; 106: 399-402
74. Schonbeck U, Varo N, Libby P et al: Soluble CD40L and cardiovascular risk in women. Circulation, 2001; 104: 2266-68
75. Mach F, Schonbeck U, Sukhova GK et al: Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature, 1998; 394: 200-3
76. Lutgens E, Gorelik L, Daemen MJ et al: Requirement for CD154 in the progression of atherosclerosis. Nat Med, 1999; 5: 1313-16
77. Dwyer JM: Manipulating the immune system with immune globulin. N Engl J Med, 1992; 326: 107-16
78. Kaveri SV, Dietrich G, Hurez V et al: Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clin Exp Immunol, 1991; 86: 192-98
79. Kazatchkine MD, Dietrich G, Hurez V et al: V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (i.v.Ig). Immunol Rev, 1994; 139: 79-107
80. Hentati B, Sato MN, Payelle-Brogard B et al: Beneficial effect of polyclonal immunoglobulins from malaria-infected BALB/c mice on the lupus-like syndrome of (NZB x NZW)F1 mice. Eur J Immunol, 1994; 24: 8-15
81. Saoudi A, Hurez V, De Kozak Y et al: Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int Immunol, 1993; 5: 1559-67
82. Nicoletti A, Kaveri S, Caligiuri G et al: Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest, 1998; 102: 910-18
83. Kwak B, Mulhaupt F, Myit S et al: Statins as a newly recognized type of immunomodulator. Nat Med, 2000; 6: 1399-402
84. Kobashigawa JA, Katznelson S, Laks H, et al: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med, 1995; 333; 621-27